Latest News on OCUL

Financial News Based On Company


Advertisement
Advertisement

Ocular Therapeutix Inc (0OT.DU) Seasonal returns chart

https://uk.finance.yahoo.com/quote/0OT.DU/seasonality/
This article provides a seasonal returns chart for Ocular Therapeutix Inc (0OT.DU) on Yahoo Finance. It displays the average monthly price return for the company between 2021 and 2026. The data is based on a delayed quote from Dusseldorf.

Weekly Recap: SOL-1 endpoints met and Q3 revenue falls, loss widens

https://www.tradingview.com/news/tradingview:831f62b144878:0-weekly-recap-sol-1-endpoints-met-and-q3-revenue-falls-loss-widens/
Ocular Therapeutix Inc (NASDAQ:OCUL) announced that its AXPAXLI treatment met key endpoints in the Phase 3 SOL-1 trial for wet AMD and plans an FDA application in Q4 2026. Despite this clinical success, the company reported a decrease in third-quarter revenue to $12.9 million and a widened net loss of $94.8 million. HC Wainwright & Co. maintained a Buy rating and raised its price target for OCUL to $28.

Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/analysts-just-slashed-their-ocular-therapeutix-inc-nasdaqocu-1
Analysts have significantly revised down their forecasts for Ocular Therapeutix, Inc. (NASDAQ:OCUL) for next year, cutting both revenue and earnings per share estimates. This downgrade reflects a more pessimistic outlook, with expected revenues of US$91m in 2027 and an increase in projected losses to US$1.57 per share. Despite the negative revisions to earnings, the consensus price target remains unchanged, suggesting analysts see the business performing in line with expectations in other areas.

Ocular Therapeutix stock hits 52-week low at 6.0 USD

https://www.investing.com/news/company-news/ocular-therapeutix-stock-hits-52week-low-at-60-usd-93CH-5026144
Ocular Therapeutix Inc. (OCUL) stock has fallen to a 52-week low of $6.00, down significantly from its high of $16.44 and experiencing a ~48% year-to-date decline. This downturn follows disappointing Q3 2026 financial results, with the company reporting a larger-than-expected adjusted loss per share and lower-than-anticipated revenue. Despite these challenges, analysts maintain a strong buy consensus with price targets ranging from $14 to $34.

Ocular Therapeutix (OCUL) Stock Looks Priced For Perfection Despite Its 202% Run

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/ocular-therapeutix-ocul-stock-looks-priced-for-perfection-de
Ocular Therapeutix (OCUL) has seen its share price climb over 200% in three years, leading to a high Price/Sales (P/S) ratio of 27.4x, significantly above the industry average. Despite a recent revenue miss and wider losses, the market appears to be pricing in significant future pipeline execution, particularly for AXPAXLI, suggesting the stock is currently very expensive based on sales. Analysts, however, have a consensus that the stock is undervalued by 75%, predicated on the successful execution and launch of AXPAXLI.
Advertisement

Ocular Therapeutix, Inc. (NASDAQ:OCUL) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/ocular-therapeutix-inc-nasdaqocul-consensus-forecasts-have-b
Ocular Therapeutix, Inc. (OCUL) recently reported third-quarter results that fell short of analyst expectations, with revenues of US$13m missing forecasts and statutory losses per share at US$0.42, 16% larger than predicted. Consequently, analysts have revised their 2027 revenue forecasts down to US$91.2m from US$102.0m and expect increased losses of US$1.55 per share, up from US$1.41. Despite these downgrades, the consensus price target remains steady at US$25.73, and the company is still expected to grow faster than the wider industry.

Ocular Therapeutix (OCUL) On Phase 3 AMD Win And Why The Valuation Debate Persists

https://sg.finance.yahoo.com/news/ocular-therapeutix-ocul-phase-3-043022588.html
Ocular Therapeutix (OCUL) recently announced a significant Phase 3 clinical milestone for AXPAXLI in wet AMD, alongside its Q3 2026 financial results showing increased net losses. Despite the clinical success and a strong 3-year shareholder return, the company faces a valuation debate due to ongoing losses and the reliance on a single late-stage asset. Analysts at Simply Wall St currently view the stock as 74% undervalued with a fair value of $25.45 per share, but acknowledge risks associated with approval timing and market uptake.

Ocular Therapeutix Inc (OCUL) Q3 2026 Earnings Call Highlights: Landmark Phase 3 Wins, NDA on ...

https://sg.finance.yahoo.com/news/ocular-therapeutix-inc-ocul-q3-010258340.html
Ocular Therapeutix Inc. (OCUL) announced landmark Phase 3 superiority results for AXPAXLI in wet AMD, demonstrating durable vision maintenance and aiming for an NDA submission in Q4 2026 with a 505(b)(2) pathway. Despite a strong cash position of $530.6 million extending into 2028, the company faces scrutiny over a changed primary endpoint in the SOL-R trial and potential challenges in market adoption amidst competition, with commercialization costs not fully factored into current cash runway projections. The earnings call also provided updates on regulatory interactions, repeat-dosing data, and the commercial strategy for AXPAXLI, positioning it as a long-term maintenance therapy.

What Ocular Therapeutix (OCUL) Said on Its Q3 Earnings Call

https://www.tradingview.com/news/marketbeat:299c547ca094b:0-what-ocular-therapeutix-ocul-said-on-its-q3-earnings-call/
Ocular Therapeutix plans to submit a U.S. application in Q4 2026 for AXPAXLI, its investigational treatment for wet age-related macular degeneration, following a pre-application meeting with the FDA. The application will leverage Phase 3 SOL-1 trial results and interim safety data from the SOL-R study. The company is also making changes to ongoing studies and preparing for a potential launch, while holding $530.6 million in cash and equivalents expected to last into 2028.

Ocular Therapeutix Posts Wider Q3 Loss as AXPAXLI Spending Climbs, Shares Slip

https://finance.biggo.com/news/72e90d15-15f2-4b47-9be0-fa708215604a
Ocular Therapeutix reported a wider-than-expected third-quarter loss of $0.42 per share and revenue of $12.9 million, missing analyst estimates, as R&D spending significantly increased for its AXPAXLI pipeline. The company is preparing for a fourth-quarter NDA submission for AXPAXLI, an investigational treatment for wet age-related macular degeneration, and expects its $530.6 million cash reserve to fund operations into 2028. Shares of the biopharmaceutical company fell 2.4% following the announcement.
Advertisement

Ocular Therapeutix falls on third quarter earnings miss By Investing.com

https://za.investing.com/news/earnings/ocular-therapeutix-falls-on-third-quarter-earnings-miss-4562416
Ocular Therapeutix Inc (NASDAQ:OCUL) reported a third-quarter earnings miss, with a loss of -$0.42 per share against an analyst consensus of -$0.36, and revenue of $12.9 million, missing the $14.3 million estimate. Shares fell 2.4% following the results. The company's net loss widened to $94.8 million due to increased R&D spending, but it remains on track to submit a New Drug Application for AXPAXLI, its investigational treatment for wet age-related macular degeneration, in Q4 2026.

Ocular Therapeutix falls on third quarter earnings miss

https://www.investing.com/news/earnings/ocular-therapeutix-falls-on-third-quarter-earnings-miss-5012700
Ocular Therapeutix Inc. (NASDAQ:OCUL) reported third-quarter results that missed Wall Street expectations, with a loss of -$0.42 per share against an estimated -$0.36, and revenue of $12.9 million, falling short of the $14.3 million estimate. The company's net loss widened to $94.8 million due to increased R&D spending on its AXPAXLI pipeline and pre-commercial preparations. Despite the miss, Ocular Therapeutix remains on track to submit a New Drug Application for AXPAXLI in wet age-related macular degeneration in Q4 2026 and expects its current cash to fund operations into 2028.

Ocular Therapeutix Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/63032007/ocular-therapeutix-q3-2026-earnings-call-transcript
Ocular Therapeutix reported significant progress in 2026, including successful Phase 3 results for Xpaxly (OTX-TKI) in wet AMD and plans to submit an NDA in Q4 2026 for potential accelerated approval. The company ended the quarter with $530.6 million in cash, extending its runway into 2028. Ocular Therapeutix is focusing on Xpaxly as a long-term maintenance therapy for wet AMD, distinct from existing anti-VEGF treatments, and is preparing for its potential commercial launch.

Ocular Therapeutix Reports Q3 2026 Results, $530.6 Million Cash Balance

https://www.tradingview.com/news/tradingview:553ffbee096a5:0-ocular-therapeutix-reports-q3-2026-results-530-6-million-cash-balance/
Ocular Therapeutix reported third-quarter 2026 revenue of $12.9 million and a net loss of $94.8 million. The company's cash and cash equivalents stood at $530.6 million as of September 30, 2026, expected to support operations into 2028. Ocular Therapeutix also announced that its AXPAXLI NDA submission for wet AMD remains on track for the fourth quarter of 2026.

OCUL: Ocular Therapeutix Inc. filed SEC Form 8-K: Results of...

https://www.quantisnow.com/insight/ocular-therapeutix-inc-filed-sec-form-8-k-results-of-operations-6780163
Ocular Therapeutix Inc. (OCUL) filed an SEC Form 8-K announcing its Q3 2026 results, reporting a net loss of $94.8 million, or $0.42 per share, with $530.6 million in cash. The company confirmed its AXPAXLI NDA submission for wet AMD is on track for Q4 2026, leveraging a 505(b)(2) pathway to shorten FDA review. While the NDA submission is progressing, AXPAXLI has not yet received marketing approval.
Advertisement

Ocular Therapeutix (NASDAQ:OCUL) reports sales below analyst estimates in Q3 2026 earnings, stock drops

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-9-ocular-therapeutix-nasdaqocul-reports-sales-below-analyst-estimates-in-q3-2026-earnings-stock-drops
Ocular Therapeutix (NASDAQ:OCUL) reported Q3 2026 earnings that fell short of analyst expectations, with revenue decreasing 11.5% year-on-year to $12.87 million and a GAAP loss of $0.42 per share. The company's stock dropped 7.4% following the announcement, reflecting concerns about missed revenue targets and deepening losses despite optimism for future growth driven by its AXPAXLI product.

Ocular Therapeutix™ Reports Third Quarter 2026 Financial Results and Business Highlights

https://www.quantisnow.com/insight/ocular-therapeutix-reports-third-quarter-2026-financial-results-and-business-6780109
Ocular Therapeutix reported a net loss of $94.8 million for Q3 2026, widening from $69.4 million a year prior, on decreased net revenue of $12.9 million. Despite the loss, the company's NDA submission for AXPAXLI in wet AMD is on track for Q4 2026, and its $530.6 million cash balance is projected to fund operations into 2028. Key figures include a Q3 2026 loss per share of $(0.42) and positive SOL-1 Week 52 topline data.

Ocular Therapeutix (OCUL) reports earnings tomorrow: what to expect

https://markets.financialcontent.com/stocks/article/stockstory-2026-11-8-ocular-therapeutix-ocul-reports-earnings-tomorrow-what-to-expect
Ocular Therapeutix (NASDAQ: OCUL), an ophthalmology biopharmaceutical company, is set to report its Q3 earnings on Monday morning. Analysts expect a 4.3% year-on-year revenue decline, an improvement from the 5.7% decrease in the same quarter last year. The company has a mixed revenue history, having beaten expectations last quarter but missed Wall Street's estimates multiple times over the last two years.

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

https://www.manilatimes.net/2026/11/06/tmt-newswire/globenewswire/ocular-therapeutix-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/2464003
Ocular Therapeutix, Inc. announced the grant of inducement equity awards to eight new non-executive employees. These awards, consisting of stock options and restricted stock units, were made under Ocular’s 2019 Inducement Stock Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4) to incentivize their employment. The awards vest over several years, subject to continued service, and aim to further the company's commitment to redefining the retina experience.

Eight new hires at Ocular Therapeutix get options for up to 35,775 shares and rights to 11,725 shares.

https://www.stocktitan.net/news/OCUL/ocular-therapeutix-tm-reports-inducement-grants-under-nasdaq-listing-ka2y6cumsy0u.html
Ocular Therapeutix, Inc. (NASDAQ: OCUL) has granted inducement equity awards to eight newly hired non-executive employees, effective November 2, 2026. These awards include options to purchase up to 35,775 shares of common stock at an exercise price of $6.73 per share, and restricted stock units representing 11,725 shares of common stock. The grants were made under the company's 2019 Inducement Stock Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), to attract and retain talent.
Advertisement

Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026

https://www.streetinsider.com/Globe+Newswire/Ocular+Therapeutix%E2%84%A2+to+Report+Third+Quarter+2026+Financial+Results+on+November+9%2C+2026/27269371.html
Ocular Therapeutix, Inc. announced it will host a conference call and webcast on Monday, November 9, 2026, at 8:00 AM ET to discuss its third-quarter 2026 financial results and recent business progress. The company is an integrated biopharmaceutical firm focusing on redefining the retina experience, with product candidates like AXPAXLI™ in Phase 3 trials for wet AMD and diabetic retinal disease.

Ocular Therapeutix™ to Report Third Quarter 2026 Financial Results on November 9, 2026

https://sg.finance.yahoo.com/news/ocular-therapeutix-report-third-quarter-120000468.html
Ocular Therapeutix, Inc. announced it will host a conference call and webcast on Monday, November 9, 2026, at 8:00 AM ET to discuss its third-quarter 2026 financial results and recent business progress. The company is an integrated biopharmaceutical firm focusing on retinal diseases with investigational product AXPAXLI™ in Phase 3 trials and commercial product DEXTENZA®.

A Nov. 9 webcast is planned to cover Ocular Therapeutix's third-quarter results.

https://www.stocktitan.net/news/OCUL/ocular-therapeutix-tm-to-report-third-quarter-2026-financial-results-wpjvt7us1g61.html
Ocular Therapeutix (NASDAQ: OCUL) announced it will host a conference call and webcast on November 9, 2026, at 8:00 AM ET to discuss its third-quarter 2026 financial results and recent business progress. The webcast will be accessible via the company's Investor Relations page, with a replay available for at least 30 days. The company is an integrated biopharmaceutical firm focusing on retinal diseases, with products like AXPAXLI™ in clinical trials and DEXTENZA® on the market.

Ocular Therapeutix, Inc. (OCUL) Seasonal Returns Chart - Yahoo Finance

https://ca.finance.yahoo.com/quote/OCUL/seasonality/
This page provides a seasonal returns chart for Ocular Therapeutix, Inc. (OCUL), displaying the average monthly price return from 2016 to 2026. It includes current stock data, after-hours trading information, and links to various research and financial tools for OCUL. The content is primarily a data presentation, not an analytical article.

Ocular Therapeutix™ to Participate in November Investor and Scientific Conferences

https://ca.finance.yahoo.com/news/ocular-therapeutix-participate-november-investor-110000142.html
Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced its participation in several upcoming investor and scientific conferences in November 2026. The company's Executive Chairman, President, and CEO, Pravin U. Dugel, MD, will present at the UBS Global Biopharma Conference, and Chief Scientific Officer, Jeffrey S. Heier, MD, will present at The Empire Forum and OSN New York & OSN New York Retina 2026, discussing the company's efforts in redefining retina care. The presentations will cover their investigational product AXPAXLI™ (OTX-TKI) for wet AMD and diabetic retinal disease, and their ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology.
Advertisement

Weekly Recap: AXPAXLI 505(b)(2) NDA filing and $600M cash runway

https://www.tradingview.com/news/tradingview:7645d9003af47:0-weekly-recap-axpaxli-505-b-2-nda-filing-and-600m-cash-runway/
Ocular Therapeutix Inc. (NASDAQ:OCUL) plans to file a 505(b)(2) NDA for AXPAXLI in Q4, a maintenance treatment for wet AMD, following positive SOL-1 trial results. The company boasts approximately $600 million in cash as of June 30, 2026, providing a runway into 2028, with options for non-dilutive funding. Needham reiterated a Buy rating with an $18 price target for OCUL, implying significant upside.

Ocular Therapeutix, Inc. Estimates – NASDAQ:OCUL

https://www.tradingview.com/symbols/NASDAQ-OCUL/financials-estimates/
This article provides an overview of financial estimates for Ocular Therapeutix, Inc. (NASDAQ:OCUL) as presented on TradingView. It details the availability of reported financial data and analyst estimates across various financial statements and valuation metrics. Users can compare actual results with average, high, and low estimates and visualize trends over time.

Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win

https://es.tradingview.com/news/marketbeat:f3292dd6a094b:0-ocular-therapeutix-eyes-q4-fda-filing-for-axpaxli-after-sol-1-win/
Ocular Therapeutix is preparing a fourth-quarter new drug application submission for AXPAXLI, its investigational maintenance treatment for wet age-related macular degeneration, following discussions with the FDA. The company's SOL-1 trial demonstrated superiority against an approved anti-VEGF therapy, and they have formalized a single-trial approval pathway with the FDA. AXPAXLI is designed as a tunable hydrogel containing a tyrosine kinase inhibitor (TKI) to address the burden of repeated anti-VEGF injections and vision loss from treatment discontinuation or disease progression.

Ocular Therapeutix (OCUL) Stock Dropped, So What Is Driving Attention Now?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/ocular-therapeutix-ocul-stock-dropped-so-what-is-driving-att/amp
Ocular Therapeutix (OCUL) is under renewed scrutiny following the resignation of its Chief Strategy Officer. The stock has seen significant short-term declines, though long-term holders still show gains. Analysts, however, largely view the stock as undervalued, with an average fair value estimate of $27.09, driven by the potential of its drug Axpaxli to capture a substantial market share in treating wet AMD.

Ocular Therapeutix (OCUL) Stock Dropped, So What Is Driving Attention Now?

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/ocular-therapeutix-ocul-stock-dropped-so-what-is-driving-att
Ocular Therapeutix (OCUL) is under renewed scrutiny following the resignation of its Chief Strategy Officer, Sanjay Nayak, on October 16, 2026. Despite recent stock drops, analysts consider OCUL significantly undervalued, with a fair value estimate of $27.09 against a current close of $6.29, primarily due to the potential of its drug Axpaxli for wet AMD. However, the company faces risks from trial stumbles or dilution due to funding needs.
Advertisement

Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Win

https://www.tradingview.com/news/marketbeat:f3292dd6a094b:0-ocular-therapeutix-eyes-q4-fda-filing-for-axpaxli-after-sol-1-win/
Ocular Therapeutix is preparing to submit a new drug application for AXPAXLI, its investigational treatment for wet age-related macular degeneration, in the fourth quarter, following positive discussions with the FDA. The company's SOL-1 trial demonstrated superiority against an approved anti-VEGF therapy, leading to a formalized single-trial approval pathway. AXPAXLI is a tunable hydrogel designed as a maintenance treatment to address the high dropout rates and vision loss associated with traditional bolus injections for wet AMD.

OCUL: Q4 2026 NDA submission on track; SOL-1 topline shifted to Q1 2028

https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:4327265:0-ocul-q4-2026-nda-submission-on-track-sol-1-topline-shifted-to-q1-2028/
Ocular Therapeutix, Inc. (OCUL) is on track for its Q4 2026 NDA submission, which remains on schedule following FDA meetings, partly due to SOL-1 demonstrating superiority over an anti-VEGF. AXPAXLI is positioned as a maintenance therapy. The topline data for SOL-1 has been amended and is now expected in Q1 2028.

Ocular Therapeutix stock hits 52-week low at 6.23 USD By Investing.com

https://za.investing.com/news/stock-market-news/ocular-therapeutix-stock-hits-52week-low-at-623-usd-93CH-4512053
Ocular Therapeutix Inc. (OCUL) stock has fallen to a 52-week low of $6.23, marking a significant decline of nearly 42% over the past year. Despite this downturn and investor concerns, InvestingPro data suggests the stock may be undervalued, with analysts setting price targets between $14 and $34. The company has also received positive analyst coverage from UBS, RBC Capital, and H.C. Wainwright for its lead asset, Axpaxli, and benefited from a competitor's trial failure.

Ocular Therapeutix stock hits 52-week low at 6.23 USD By Investing.com

https://ca.investing.com/news/stock-market-news/ocular-therapeutix-stock-hits-52week-low-at-623-usd-93CH-4888694
Ocular Therapeutix Inc. (OCUL) stock has fallen to a 52-week low of $6.23, marking a significant 42% decline over the past year and trading 62% below its 52-week high. Despite the downturn, InvestingPro data suggests the stock may be undervalued, with analysts setting price targets between $14 and $34. The company has recently received positive analyst coverage from UBS, RBC Capital, and H.C. Wainwright, especially regarding its lead asset, Axpaxli, and its potential in the wet age-related macular degeneration market.

Ocular Therapeutix stock hits 52-week low at 6.23 USD By Investing.com

https://ng.investing.com/news/stock-market-news/ocular-therapeutix-stock-hits-52week-low-at-623-usd-93CH-2743888
Ocular Therapeutix Inc. (OCUL) stock has fallen to a 52-week low of $6.23, marking a nearly 42% decline over the past year. Despite investor concerns reflected in the stock performance, InvestingPro data suggests the stock may be undervalued, with analysts setting price targets between $14 and $34. The company has also received positive analyst coverage from UBS, RBC Capital, and H.C. Wainwright regarding its lead asset, Axpaxli, for retinal therapy.
Advertisement

Ocular Therapeutix (OCUL) Stock May Be Fully Priced Given Its Sales Base

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ocul/ocular-therapeutix/news/ocular-therapeutix-ocul-stock-may-be-fully-priced-given-its
Ocular Therapeutix (OCUL) stock's recent 192.3% gain over three years has led to questions about whether its current valuation of US$6.87 is justified by its sales base. The company, which is still loss-making, trades at a high P/S ratio of 29.0x compared to the Pharmaceuticals industry average of 4.3x, suggesting it may be overvalued when adjusting for growth potential, margins, size, and risk. Analysts and Simply Wall St's models indicate that the current price heavily relies on future pipeline success and commercial strategy rather than present revenue.

Sanjay Nayak resigns as Chief Strategy Officer at Ocular Therapeutix

https://www.tradingview.com/news/tradingview:7248d368c0161:0-sanjay-nayak-resigns-as-chief-strategy-officer-at-ocular-therapeutix/
Ocular Therapeutix announced that Sanjay Nayak has resigned from his position as Chief Strategy Officer, effective October 16, 2026. Nayak is leaving to become the Chief Executive Officer of a privately-held company. His replacement has not yet been disclosed.

Gross profit of Ocular Therapeutix Inc – HAN:0OT

https://www.tradingview.com/symbols/HAN-0OT/financials-income-statement/gross-profit/
This article provides a brief financial overview of Ocular Therapeutix Inc (HAN:0OT) on the Hannover Stock Exchange, specifically focusing on its gross profit. The content confirms the market was closed at the time of publication with no trades recorded. It indicates that further financial details, documents, news, and community discussions are available elsewhere on the platform.

Long term debt to total equity ratio of Ocular Therapeutix Inc – HAN:0OT

https://www.tradingview.com/symbols/HAN-0OT/financials-statistics-and-ratios/long-term-debt-to-equity/
The article provides financial data for Ocular Therapeutix Inc (HAN:0OT) on the Hannover Stock Exchange, specifically focusing on its long-term debt to total equity ratio. It indicates that the market was closed with no trades at the time of reporting. The data is sourced from ICE Data Services and FactSet Research Systems Inc.

Form 4 Ocular Therapeutix Inc: Todd Anderman (CLO) For: 8 October

https://ng.investing.com/news/stock-market-news/form-4-ocular-therapeutix-inc-todd-anderman-clo-for-8-october-93CH-2735003
This article reports on a Form 4 filing for Ocular Therapeutix Inc, specifically detailing a transaction by Todd Anderman, the company's Chief Legal Officer, on October 8. It provides the financial data point for OCUL, which was down 6.91%. The content is brief and serves as an announcement of the insider trading report.
Advertisement

Ocular Therapeutix CLO Todd Anderman sells $87,363 in company stock By Investing.com

https://in.investing.com/news/stock-market-news/ocular-therapeutix-clo-todd-anderman-sells-87363-in-company-stock-93CH-5631800
Todd Anderman, Chief Legal Officer of Ocular Therapeutix (NASDAQ:OCUL), sold 11,984 shares totaling $87,363 to cover tax obligations from restricted stock unit vesting. Following these transactions, Anderman retains 140,484 shares. This sale occurs as OCUL shares have dropped 40% year-to-date, though InvestingPro analysis suggests the stock is currently undervalued.

Form 4 Ocular Therapeutix Inc: Todd Anderman (CLO) For: 8 October

https://in.investing.com/news/stock-market-news/form-4-ocular-therapeutix-inc-todd-anderman-clo-for-8-october-93CH-5631804
This article reports on a Form 4 filing for Ocular Therapeutix Inc, specifically detailing a transaction by Todd Anderman, the company's Chief Legal Officer, on October 8th. The brief notice from Investing.com indicates this as a significant insider transaction.

Ocular Therapeutix CLO Todd Anderman sells $87,363 in company stock

https://www.investing.com/news/insider-trading-news/ocular-therapeutix-clo-todd-anderman-sells-87363-in-company-stock-93CH-4947932
Ocular Therapeutix's Chief Legal Officer, Todd Anderman, sold 11,984 shares of the company's common stock for $87,363 on October 8, 2026. This transaction was to cover tax withholding obligations related to restricted stock units and was not a discretionary sale. The sale occurred as OCUL shares have dropped 40% year-to-date, though InvestingPro analysis suggests the stock is currently undervalued.

To cover vesting taxes, Ocular Therapeutix (OCUL) legal chief sold 11,984 shares.

https://www.stocktitan.net/sec-filings/OCUL/form-4-ocular-therapeutix-inc-insider-trading-activity-4a9bc36fdfdf.html
Ocular Therapeutix's Chief Legal Officer, Todd Anderman, sold 11,984 shares of common stock on October 8, 2026, at a weighted average price of $7.29 per share. This sale was not a discretionary trade but was executed to cover tax withholding obligations associated with restricted stock units that vested the day before. Following the transaction, Anderman directly holds 140,484 shares.

Average basic shares outstanding of Ocular Therapeutix Inc – HAN:0OT

https://www.tradingview.com/symbols/HAN-0OT/financials-income-statement/basic-shares-outstanding/
This article provides a brief financial overview of Ocular Therapeutix Inc (0OT) on the Hannover Stock Exchange. It specifically highlights the average basic shares outstanding for the company, indicating that the market was closed with no trades at the time of publication. The information is presented within a financial data platform interface.
Advertisement

OCUL Initiates Coverage On UBS -- Price Target Announced at $14.00

https://www.gurufocus.com/news/9119179/ocul-initiates-coverage-on-ubs-price-target-announced-at-1400
UBS has initiated coverage on Ocular Therapeutix (OCUL) with a "Buy" rating and a price target of $14.00. However, GuruFocus indicates that OCUL is currently 70.2% overvalued with a GF Value™ of $4.43 and a low profitability rank, suggesting investors should proceed with caution despite the positive analyst outlook. The company's GF Score™ of 55/100 points to average performance, with strengths in growth and momentum but weaknesses in valuation and profitability.

UBS Initiates Coverage on Ocular Therapeutix With Buy Rating, $14 Price Target

https://www.moomoo.com/news/post/1000932169/ubs-initiates-coverage-on-ocular-therapeutix-with-buy-rating-14
UBS has initiated coverage on Ocular Therapeutix (NASDAQ: OCUL) with a Buy rating and a $14 price target. This new coverage suggests a positive outlook from UBS on the pharmaceutical company's future performance and stock value.

UBS initiates Ocular Therapeutix stock with buy rating on Axpaxli potential

https://www.investing.com/news/analyst-ratings/ubs-initiates-ocular-therapeutix-stock-with-buy-rating-on-axpaxli-potential-93CH-4943283
UBS has initiated coverage on Ocular Therapeutix (NASDAQ:OCUL) with a buy rating and a $14 price target, driven by the strong potential of its lead asset, Axpaxli, as a long-acting retinal therapy with a projected $20 billion U.S. total addressable market. The stock, currently trading at $7.54, presents an 86% upside to UBS's target, with analysts anticipating $3.3 billion in total sales by 2035. Recent positive Phase 3 trial results for wet age-related macular degeneration and a credible regulatory path further support this optimistic outlook.

Total debt per share of Ocular Therapeutix Inc – HAN:0OT

https://www.tradingview.com/symbols/HAN-0OT/financials-statistics-and-ratios/total-debt-per-share/
This article provides financial information for Ocular Therapeutix Inc. on the Hannover Stock Exchange under the ticker 0OT. It specifically mentions "Total debt per share" as a key financial metric but does not provide the actual value. The article outlines the source of market and reference data, crediting ICE Data Services and FactSet.

Form 144 OCULAR THERAPEUTIX For: 10 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-ocular-therapeutix-for-10-october-93CH-4874413
This article announces the filing of Form 144 for OCULAR THERAPEUTIX (OCUL) on October 10. Form 144 is a notice of the intent to sell restricted securities. The brief article, published by Investing.com, indicates this financial action for the company.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement